Previous 10 | Next 10 |
The following slide deck was published by Geron Corporation in conjunction with their 2021 Q2 earnings call. For further details see: Geron Corporation 2021 Q2 - Results - Earnings Call Presentation
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced three poster presentations related to imetelstat, the Company’s first in class telomerase inhibito...
Geron (NASDAQ:GERN) appointed 25-years industry veteran Edward Koval as EVP & chief business officer; his business development expertise, extensive industry network and successful track record in corporate deal-making further strengthens the company's executive team. "...
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the appointment of Edward Koval as Executive Vice President and Chief Business Officer. “Ed Ko...
Geron continues to stay the course with their blood cancer drug. Released abstracts for ASH 2021 suggest it will be a quiet winter for the company. No major catalysts should be anticipated for the near term, indicating that neutral to bearish sentiment should be the play. Fo...
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will present a company ...
Shares of Geron (GERN -6.2%) are down today even though the company beat on EPS and revenues estimates for Q3 2021 after the bell yesterday. The company's net loss widened in the quarter ~36% to $26.7M (-$0.08 per share). Operating expenses increased ~28% to $25.8M. The company ende...
AerSale (NASDAQ:ASLE) -36% on Q3 earnings release. Purple Innovation (NASDAQ:PRPL) -32% on Q3 earnings release. Poshmark (NASDAQ:POSH) -30% on Q3 earnings release. Upstart Holdings (NASDAQ:UPST) -23% on Q3 earnings release. AnPac Bio-Medical S...
Geron (NASDAQ:GERN): Q3 GAAP EPS of -$0.08 beats by $0.01. Revenue of $0.11M (flat Y/Y) beats by $0.05M. Press Release For further details see: Geron EPS beats by $0.01, beats on revenue
Strong Evidence of Disease-Modifying Activity of Imetelstat Provides Compelling Differentiation for Phase 3 Development Programs in Lower Risk MDS and Refractory MF Significant Unmet Needs in Lower Risk MDS and Refractory MF Addressable by Imetelstat Provide Potential ...
News, Short Squeeze, Breakout and More Instantly...
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of Spirit Airlines, Inc. (NYSE:SAVE) fell sharply duri...
2024-05-03 00:30:12 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q1 2024 Earnings Call May 02, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Geron (GERN) Q1 2024 Earnings Call Transcript
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...